Business Segments CSPC Pharmaceutical Group Limited

Stocks

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2026-07-24 EDT			5-day change	1st Jan Change
8.550 ^HKD	+2.15%		+5.56%	+1.42%

07-24	CSPC Pharmaceutical Group Limited Announces Marketing Approval For Paliperidone Palmitate Injection	CI
07-22	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of Sys6026 Injection for HPV Type 16 or 18 Related Cervical High Grade Squamous Intraepithelial Lesion in China	CI

Breakdown by Business Segment (HKD)

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Pharmaceutical Products
Finished Drugs	22.68B	24.52B	25.64B	23.74B	20.58B
D&A	610M	751M	802M	1.01B	1.08B
Operating Income	5.22B	6.07B	6.7B	4.83B	3.87B
Bulk Products - Antibiotics	-	-	2.01B	1.77B	1.57B
D&A	-	-	76.62M	81.58M	82.13M
Operating Income	-	-	154M	299M	184M
Caffeine and Others	-	-	-	-	-
D&A	-	-	-	-	-
Operating Income	-	-	-	-	-
Raw Material Product - Antibiotics and Others	1.85B	2.21B	-	-	-
D&A	92.8M	99.93M	-	-	-
Operating Income	143M	190M	-	-	-
Vitamins and Nutritional Supplements
Bulk Products - Vitamin C	2.16B	2.53B	1.94B	2.03B	2.23B
D&A	86.33M	123M	155M	169M	162M
Operating Income	742M	443M	4.95M	211M	192M
Functional Food and Others	1.39B	2.05B	2.47B	1.86B	1.82B
D&A	66.68M	64.03M	74.11M	65.35M	82.17M
Operating Income	316M	572M	562M	305M	276M
Eliminations	-216M	-375M	-612M	-395M	-201M
Operating Income	-	-	-	-	-
Operating Income	-	-	-	-	-
D&A	9.78M	9.71M	9.86M	9.91M	9.89M
Inorganic Dyes and Pigments
Others	-	-	-	-	-
D&A	-	-	-	-	-
Operating Income	-	-	-	-	-

Geographical breakdown of sales (HKD)

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Mainland China	24.29B	26.14B	27.18B	25.11B	20.83B
Total Assets	14.41B	17.81B	19.54B	22.5B	24.45B
Europe	700M	1.27B	1.28B	1.31B	2.43B
Other Asian Regions	1.47B	1.74B	1.58B	1.18B	1.26B
North America	-	-	882M	853M	890M
Others	244M	284M	525M	554M	596M
Americas	-	1.51B	-	-	-
United States of America (“USA”)	1.16B	-	-	-	-